GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash

GlaxoSmithKline, 05/11/2012

GlaxoSmithKline plc announced that it has commenced its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences for US$13.00 per share in cash. GSK's offer represents a premium of 81 percent to HGS's closing share price of US$7.17 on 18th April, the last trading day before HGS publicly disclosed GSK's private offer.

Print Article Summary Cat 2 CME Report